<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83864">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01765049</url>
  </required_header>
  <id_info>
    <org_study_id>SNUHBCC001</org_study_id>
    <nct_id>NCT01765049</nct_id>
  </id_info>
  <brief_title>Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor</brief_title>
  <acronym>DEAR</acronym>
  <official_title>Prospective Study Analyzing Value of Breast Density Change Predicting ENdocrine Therapy Response in Postmenopausal Women Taking Adjuvant ARomatase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast density change after short term use of aromatase inhibitor in postmenopausal ER
      positive breast cancer would predict endocrine responsiveness
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria ER positive breast cancer Postmenopause women Older than 60yr S/P
      bilateral salphingo-oophorectomy No menstruation history within 1yr and FSH&gt;30mIU/mL
      Ipsilateral invasive breast cancer Undergone curative resection No evidence of distant
      metastasis Capable of breast MRI
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>5 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>recurrence locoregional distant metastasis Confirmed by clinical imaging or pathology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>breast density change</measure>
    <time_frame>6mos, 1yr, 2yr</time_frame>
    <safety_issue>No</safety_issue>
    <description>breast density change measured by cumulus(mammogram) and MRI(bilateral breast MRI) imagings taken after 6mos, 1yr, 2yr after endocrine therapy initiation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>overall survival</measure>
    <time_frame>5 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>disease specific survival overall survival during 5yr follow up</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">411</enrollment>
  <condition>Invasive Breast Cancer</condition>
  <condition>Estrogen Receptor Positive</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Postoperatively collected specimen (normal and cancer tissue) Preoperatively collected blood
      sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Postmenopausal women with ER positive invasive breast cancer taking adjuvant endocrine
        therapy with aromatase inhibitor
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ER positive invasive breast cancer Postmenopause women age 60yrs or older s/p
             bilateral salphingo-oophorectomy No history of menstruation and FSH&gt;30mIU Planned for
             aromatase inhibitor Unilateral breast cancer Curative resection No evidence of
             distant metastasis

        Exclusion Criteria:

          -  Bilateral breast cancer Male breast cancer Acceptable for breast MRI Pregnancy or
             lactation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wonshik Han, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNUH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wonshik Han, MD PhD</last_name>
    <phone>82-2-2072-1958</phone>
    <email>hanw@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jisun Kim, MD MS</last_name>
    <phone>82-2-2072-4755</phone>
    <email>leticeclear@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jung-Hee Cha, MS</last_name>
      <phone>82-2-2072-0694</phone>
      <email>snuirb@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 8, 2013</lastchanged_date>
  <firstreceived_date>January 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast density change</keyword>
  <keyword>endocrine therapy response</keyword>
  <keyword>aromatase inhibitor</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
